MedPath

TO ANALYSIS THE PSORIASIS WITH SIDDHA CONCEPT

Completed
Conditions
Psoriasis, unspecified,
Registration Number
CTRI/2018/06/014496
Lead Sponsor
Ayothidoss Pandithar Hospital
Brief Summary

Psoriasis is a challenge for the physician,becausechronic generalized psoriasis is one of the miseries that beset mankind causingshame, embarrassment and compromised life style. From available studies,prevalence of psoriasis in India ranges from 0.44% to 2.8%  it is twice more common in males compared tofemales. In text book of siddha maruthuva sirappu female are commonly affected.but in our study  female 30% male 70%.Highest   prevalence was noted in the age group of21-30 and 41-50 years. In our study was 26-45 years and 46-65 years. 12.5% hadfamily history in other study. In our study was 9.5% had a family history .Inmodern concept ,chronic plaque psoriasis was the most common (50%)clinicalpattern. In Siddha concept our study AZHAL KALANJAGAPADAI was common.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
200
Inclusion Criteria

patients with psoriasis complaint.

Exclusion Criteria

Not provided

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Based on Sirappu Maruthuvam text there is no classification of kalanjagapadai. Here I try to classify Kalanjagapadai into three category of Vali, azhal, Iyam by its characteristics features. Medicines selection to kalanjagapadai is vary in people to people.The classification of Kalanjagapadai based on tridosham to improve diagnostic quality and also helpful easy to select medicine.15 to 20 minutes
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Ayothidoss pandithar hospital

🇮🇳

Chennai, TAMIL NADU, India

Ayothidoss pandithar hospital
🇮🇳Chennai, TAMIL NADU, India
Dr M Sujitha
Principal investigator
8940164101
mk.suji5@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.